Nov 01, 2019 / 04:00AM GMT
Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences
Nov 01, 2019 / 04:00AM GMT
=====================
Corporate Participants
=====================
* Hiroshi Nomura
Sumitomo Dainippon Pharma Co., Ltd. - CEO, President & Representative Director
=====================
Conference Call Participants
=====================
* Fumiyoshi Sakai
Crédit Suisse AG, Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Motoya Kohtani
Nomura Securities Co. Ltd., Research Division - Senior Analyst
* Seiji Wakao
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Research Division - Senior Analyst
* Shinichiro Muraoka
Morgan Stanley, Research Division - Research Analyst
* Stephen Marks
Jefferies LLC - Investment Banking Analyst
* Yasuhiro Nakazawa
SMBC Nikko Securities Inc., Research Division - Senior Analyst
* Myrtle Potter;CEO
* Vivek Ramaswamy
Roivant
Roivant Sciences Ltd
(NAS:ROIV)
$
35.39
+0.26 (+0.74%)
Market Cap: 25.45 Bil
Enterprise Value: 22.04 Bil
PE Ratio: 0
PB Ratio: 5.63
GF Score: 51/100 Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences Transcript
Nov 01, 2019 / 04:00AM GMT
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot